Grifols to sell assets under FTC agreement for Talecris merger
This article was originally published in Scrip
Executive Summary
After agreeing to sell certain assets, Spanish firm Grifols won a tentative approval from the US Federal Trade Commission (FTC) under a consent agreement to buy North Carolina biotech Talecris Biotherapeutics for about $4 billion (scripintelligence, 7 June 2010).